



SCIENTIFIC LETTER

**Percutaneous versus surgical closure
of patent ductus arteriosus in
low-weight premature infants:
10-year experience in a tertiary
center**



**Cierre percutáneo versus quirúrgico del
ductus arterioso persistente en prematuros de
bajo peso: experiencia de 10 años en un
centro de tercer nivel**

Dear Editor:

Patent ductus arteriosus (PDA) is a condition that can give rise to an imbalance in the pulmonary to systemic flow ratio (Qp/Qs), with an increase in pulmonary blood flow and a decrease in systemic blood flow. In preterm newborns, it can be associated with important complications such as pulmonary haemorrhage, bronchopulmonary dysplasia, necrotising enterocolitis, impaired renal function and intraventricular haemorrhage, among others.¹ Its management and the indications for treatment remain controversial.² Thanks to the improvement of techniques and the availability of novel devices, percutaneous closure (PC) has become one of the treatment options of choice in cases in which pharmacological closure is unsuccessful.³

In this article, we analyse the experience of our hospital with both approaches over a 10-year period (2012–2022), describing the outcomes of PC and surgical closure (SC). To this end, we included 58 preterm infants with a diagnosis of PDA without associated cardiac defects. We reviewed the health records to collect data on clinical outcomes during the hospital stay, such as the need for respiratory support or inotropic agents and postoperative complications.

A total of 43 SCs and 15 PCs were performed during the study period. Until 2018, SC was the only procedure performed. In 2019, the first PC took place (Fig. 1). Table 1 presents the characteristics and main clinical outcomes analysed in the sample.

We did not compare both techniques since they involved 2 historical cohorts that were very different. We found higher values for patients in the PC group for postmenstrual age

($P = .0012$), weight ($P = .008$) and days of chronological age ($P = .0005$) at the time of the procedure. In spite of this, the clinical outcomes in each group based on some of the main indicators of severity (central line days, mechanical ventilation days, days of inotropic treatment, etc) did not differ between the two cohorts.

The overall incidence of complications in our study, including both techniques, was 38%. Table 1 describes the most frequent complications.

Some complications are specific to one of the procedures. In the case of SC, the most frequently described complications are post-ligation syndrome, pneumothorax, chylothorax, atelectasis, infection, bleeding, diaphragmatic paralysis and vocal cord paralysis secondary to damage of the left recurrent laryngeal nerve.⁴ In our sample, the incidence of complications in this group was 42%, and the most frequent complications were post-ligation syndrome, infections and respiratory complications (bronchopulmonary dysplasia), with an overall percentage (44%) similar to previous reports in the literature.⁴ We ought to highlight that there were no cases of chylothorax, pneumothorax or surgical wound infection.

As regards the complications associated with PC, device embolization, obstruction of the aorta or left pulmonary artery by a protruding device, tricuspid valve damage and persistent residual ductal flow are the most common ones. The literature describes a rate of complications of up to 33%, which is slightly higher than the one observed in our cohort, of 27%.⁵

Lastly, the mortality in the sample was 7%, which was consistent with the previous literature.⁶

In this article, we describe the experience in our hospital with nonpharmacological PDA closure through these 2 therapeutic approaches over a period of 10 years. During this time, we observed a change in the management of cases refractory to medical treatment, switching from SC to PC (Fig. 1). These trends have also been described by other authors and it is associated with the development and improvement of PC.⁴ We also ought to mention that postmenstrual age, the days of chronological age and the weight of patients at the time of the procedure were significantly greater in the PC group. This could be explained by the more restrictive indications for PDA closure currently applied in most neonatal units.




Figure 1 Number of procedures per year by type of intervention. Temporal trends in type of intervention.

Table 1 Characteristics of the sample. Complications by group.

Variable	Total (n = 58)	Surgical closure (n = 43)	Percutaneous closure (n = 15)	P
Demographic characteristics				
Gestational age at birth	26.2 ± 2.2	26.1 ± 2.3	26.25 ± 2.2	.93
Birth weight	819 ± 262	814.76 ± 254	831.8 ± 294	.8311
Sex (female)	46.55%	46.51%	46.67%	.991
Outborn infant	48.28%	37.21%	80%	.004*
Death	7.02%	6.98%	7.14%	.983
Postmenstrual age at time of procedure	30.7 ± 4.4	29.84 ± 2.9	33.12 ± 3.8	.0012*
Weight on day of procedure	1165.2 ± 482	1065.72 ± 426	1443 ± 534	.008*
Days of life at time of procedure	32.3 ± 21.5	26.76 ± 13.66	48.2 ± 30.96	.0005*
Clinical characteristics				
Days of central line after procedure	15.05 ± 17.15	16.10 ± 18	10 ± 8.2	.4359
Days of ventilation after procedure	8.6 ± 1.88	9.35 ± 14.23	6.4 ± 6.11	.4827
Days of inotropic support after procedure	1.5 ± 0–11	1.11 ± 1.2	2.5 ± 3.77	.1623
Days of sedation after procedure	7.5 ± 1–26	7.32 ± 6.2	7.9 ± 8.3	.8173
Incidence of complications				
Overall	37% (22)	42% (18)	27% (4)	
Tricuspid valve regurgitation	0	0	2% (1)	
Respiratory (bronchopulmonary dysplasia)	10% (6)	14% (4)	13% (2)	
Infectious (nosocomial infection)	8% (5)	16% (5)	0	
Haemorrhage (after procedure)	3% (2)	5% (2)	0	
Device migration	1% (1)	0	2% (1)	
Vocal cord paralysis	5% (3)	7% (3)	0	
Post-ligation syndrome	10% (6)	14% (4)	13% (2)	
Pericardial effusion	1% (1)	0	2% (1)	

Values expressed as percentage or mean ± standard deviation. (*) Statistically significant result.

Percutaneous closure of PDA is the procedure of choice for definitive ductal closure in adults, children and infants weighing more than 6 kg. In the past decade, the evidence on the safety and viability of percutaneous PDA closure in early childhood and even in preterm infants has been mounting. Given the favourable outcomes and low rate of complications, at present the minimum weight considered required in infants for performing the procedure continues to decrease. Several clinical trials have contributed safety and efficacy data for PC devices in patients weighing between 700 g and 2 kg, and PC has become the standard of care in the management of PDA for this subset of patients in many centres.³

The introduction of PC as a treatment for PDA in our hospital appears to be an effective strategy with a rate of complications similar to that reported in the recent literature.⁵

The long-term follow-up of these patients will be of vital importance for the purpose of achieving more complete understanding of the safety and effectiveness of both techniques.

Funding

This research did not receive any external funding.

References

1. Terrin G, Di Chiara M, Boscarino G, Metrangolo V, Faccioli F, Onestà E, et al. Morbidity associated with patent ductus arteriosus in preterm newborns: a retrospective case-control study. *Ital J Pediatr.* 2021;47:1.
 2. Lopata SM, Slaughter JC, Gillam-Krakauer M, Reese J. The patent ductus arteriosus management debate: it's not over yet. *J Perinatol.* 2021;41:923–5.
 3. Sathanandam SK, Gutfinger D, O'Brien L, Forbes TJ, Gillespie MJ, Berman DP, et al. Amplatzer Piccolo Occluder clinical trial for percutaneous closure of the patent ductus arteriosus in patients ≥ 700 grams. *Catheter Cardiovasc Interv.* 2020;96(6):1266–76.
 4. Hamrick SEG, Sallmon H, Rose AT, Porras D, Shelton EL, Reese J, et al. Patent ductus arteriosus of the preterm infant. *Pediatrics.* 2020;146(5).
 5. Backes CH, Cheatham SL, Deyo GM, Leopold S, Ball MK, Smith CV, et al. Percutaneous patent ductus arteriosus (PDA) closure in very preterm infants: Feasibility and complications. *J Am Heart Assoc.* 2016;5(2).
 6. Pavlek LR, Slaughter JL, Berman DP, Backes CH. Catheter-based closure of the patent ductus arteriosus in lower weight infants. *Semin Perinatol.* 2018;42:262–368.
- Sara C. Forero-Florez, Madeleine A.Z. Ball,
María Clara Escobar-Díaz, Joan Sanchez-de-Toledo,
Juan Carretero, Marta Camprubí-Camprubí*
- Servicios de Cardiología y Neonatología, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain*
- * Corresponding author.
E-mail address: [\(M. Camprubí-Camprubí\).](mailto:marta.camprubi@sjd.es)
- 13 May 2024 20 June 2024